The 4E-BP2 antibody is a crucial tool in studying the eukaryotic initiation factor 4E (eIF4E)-binding protein family, particularly 4E-BP2 (eIF4E-binding protein 2). 4E-BP2. along with 4E-BP1 and 4E-BP3. regulates cap-dependent translation by binding to eIF4E, a key component of the translation initiation complex. This interaction inhibits eIF4E from assembling the eIF4F complex, thereby suppressing mRNA translation. The phosphorylation status of 4E-BP2. modulated by mTORC1 signaling, determines its binding affinity to eIF4E. Dysregulation of this pathway is implicated in cancers, neurodegenerative diseases, and metabolic disorders.
The 4E-BP2 antibody enables researchers to detect and quantify endogenous 4E-BP2 protein levels, assess its phosphorylation state, and study its role in cellular processes like proliferation, autophagy, and stress responses. Its specificity is critical due to high sequence homology among 4E-BP isoforms. Studies using this antibody have revealed tissue-specific expression patterns, with 4E-BP2 being abundant in the brain, suggesting unique roles in neuronal function. Recent work highlights its involvement in cancer resistance mechanisms when 4E-BP1 is inhibited, making it a potential therapeutic target. The antibody is widely applied in Western blotting, immunoprecipitation, and immunofluorescence, advancing our understanding of translational control in health and disease.